Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 1
2011 6
2012 2
2013 6
2014 8
2015 11
2016 9
2017 10
2018 8
2019 9
2020 19
2021 20
2022 32
2023 26
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis.
Galli M, Laborante R, Ortega-Paz L, Franchi F, Rollini F, D'Amario D, Capodanno D, Tremoli E, Gibson CM, Mehran R, Angiolillo DJ. Galli M, et al. Thromb Haemost. 2023 Jun;123(6):576-584. doi: 10.1055/a-2043-0346. Epub 2023 Feb 25. Thromb Haemost. 2023. PMID: 36841245
BACKGROUND: Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes. ...
BACKGROUND: Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were …
Thrombophilia Testing - a Systematic Review.
Asmis L, Hellstern P. Asmis L, et al. Clin Lab. 2023 Apr 1;69(4). doi: 10.7754/Clin.Lab.2022.220817. Clin Lab. 2023. PMID: 37057948 Review.
Tests involved include the natural anticoagulants antithrombin, protein C, and protein S; the procoagulants fibrinogen (dysfibrinogen), prothrombin (mutation G20210A), factor V (Leiden mutation), factor VIII/von Willebrand factor/blood group ABO, factor …
Tests involved include the natural anticoagulants antithrombin, protein C, and protein S; the procoagulants fibrinogen (dysfibrinogen), prot …
Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis.
Liang J, Wu S, Feng B, Lei S, Luo G, Wang J, Li K, Li X, Xie H, Zhang D, Wang X, Wu K, Miao D, Fan D. Liang J, et al. J Gastroenterol. 2011 Oct;46(10):1158-66. doi: 10.1007/s00535-011-0441-7. Epub 2011 Jul 30. J Gastroenterol. 2011. PMID: 21805067 Review.
BACKGROUND: Recent studies proved that inflammatory bowel disease (IBD) patients had a higher risk of thromboembolism and a Factor V Leiden mutation that prevents the efficient inactivation of factor V, which leads to thromboembolism and thus contributes to a high p …
BACKGROUND: Recent studies proved that inflammatory bowel disease (IBD) patients had a higher risk of thromboembolism and a Factor V …
Gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review.
Wiewel-Verschueren S, Arendz IJ, M Knol H, Meijer K. Wiewel-Verschueren S, et al. Haemophilia. 2016 Mar;22(2):188-195. doi: 10.1111/hae.12856. Epub 2015 Dec 3. Haemophilia. 2016. PMID: 26634881 Review.
INTRODUCTION: Menstrual bleeding, pregnancy and delivery present an intrinsic haemostatic challenge to women with bleeding disorders such as factor XI (FXI) deficiency. AIM: To provide a systematic overview of studies on gynaecological and obstetrical bleeding probl …
INTRODUCTION: Menstrual bleeding, pregnancy and delivery present an intrinsic haemostatic challenge to women with bleeding disorders such as …
Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis.
Presume J, Ferreira J, Ribeiras R, Mendes M. Presume J, et al. J Thromb Haemost. 2022 Dec;20(12):2930-2938. doi: 10.1111/jth.15890. Epub 2022 Oct 5. J Thromb Haemost. 2022. PMID: 36128769 Free PMC article.
BACKGROUND: In recent years, many important advances have been seen in anticoagulation therapy. However, bleeding risk is still a major concern. Factor XI (FXI) inhibition has emerged as a potential advantageous target to minimize this risk. ...Incidence of adverse …
BACKGROUND: In recent years, many important advances have been seen in anticoagulation therapy. However, bleeding risk is still a major conc …
Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review.
Bosch A, Uleryk E, Avila L. Bosch A, et al. Res Pract Thromb Haemost. 2023 Feb 2;7(2):100064. doi: 10.1016/j.rpth.2023.100064. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 36852262 Free PMC article.
OBJECTIVE: The goal of this systematic review is to investigate the predictive role of FVIII, IX, or XI in recurrent VTE in adult and pediatric patients with a first VTE. ...
OBJECTIVE: The goal of this systematic review is to investigate the predictive role of FVIII, IX, or XI in recurrent VTE in adult and …
Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors.
Franco-Moreno A, Muñoz-Rivas N, Torres-Macho J, Bustamante-Fermosel A, Ancos-Aracil CL, Madroñal-Cerezo E. Franco-Moreno A, et al. Rev Clin Esp (Barc). 2024 Mar;224(3):167-177. doi: 10.1016/j.rceng.2024.01.006. Epub 2024 Feb 1. Rev Clin Esp (Barc). 2024. PMID: 38309621 Review.
INTRODUCTION AND OBJECTIVE: Data from phase 2 clinical trials suggest that factor XI inhibitors may exhibit a more favorable efficacy/safety profile compared to current antithrombotic therapies. ...Evidence from 8 studies with available results was analyzed. Phase 2 …
INTRODUCTION AND OBJECTIVE: Data from phase 2 clinical trials suggest that factor XI inhibitors may exhibit a more favorable e …
Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis.
Jin Y, Sun F, Yang A, Yu X, Li Y, Liang S, Jing X, Wang K, Zhang L, Xiao S, Zhang W, Wang X, Zhao G, Gao B. Jin Y, et al. Front Endocrinol (Lausanne). 2023 Dec 15;14:1279717. doi: 10.3389/fendo.2023.1279717. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38174331 Free PMC article.
BACKGROUND: Insulin-like growth factor binding protein-1 (IGFBP-1) is considered a decline in polycystic ovary syndrome (PCOS), but it remains controversial that whether such reduction is attributed to obesity. ...
BACKGROUND: Insulin-like growth factor binding protein-1 (IGFBP-1) is considered a decline in polycystic ovary syndrome (PCOS), but i …
Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis.
Kou H, Huang L, Jin M, He Q, Zhang R, Ma J. Kou H, et al. Front Immunol. 2023 May 31;14:1121655. doi: 10.3389/fimmu.2023.1121655. eCollection 2023. Front Immunol. 2023. PMID: 37325651 Free PMC article.
The activity of rheumatoid arthritis was assessed using erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), protein, disease activity score (DAS), rheumatoid factor (RF), Visual Analogue Scale (VAS) pain, tender joint count (TJC) and swollen joint count (SJC). …
The activity of rheumatoid arthritis was assessed using erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), protein, disease act …
163 results